European stocks traded lower on Friday amid growing concerns about the impact of the micronutrient on the economic recovery and central bank announcements of emergency stimulus measures taken in the wake of the coronavirus crisis to support them.
European indices closed higher yesterday after the monetary policy decisions of the European Central Bank and the Bank of England.
The ECB has also officially announced that the Extraordinary Bond Purchase Program (PEPP) will expire in March 2022, while at the same time decided to strengthen the regular purchasing program (APP) in order to avoid any negative effects from the gradual contraction of PEPP.
The Bank of England also surprised investors by moving on raising interest rates for the first time since the outbreak of the pandemic. The bank cited the strong labor market and the need to return inflation to the 2% target. Data released in November showed prices jumping to a 10-year high of 5.1%.
On the board, the pan-European Stoxx 600 index moves with small losses of 0.3%, at 475.33 points.
The German DAX also fell 0.3% to 15,593.38 points, the French CAC 40 recorded marginal gains of 0.02% to 7,006.29 points, while the British FTSE 100 gained 0.2% to 7,277.13 points.
In the periphery, the Italian FTSE MIB loses 0.5%, while the Spanish IBEX 35 falls 0.6%.
Investors, meanwhile, are watching the new micron mutation as it continues to spread at an alarming rate, forcing many countries to return to austerity measures to avoid a new tsunami.
The President of the European Commission, Ursula von der Leyen, speaking at the press conference after the summit of EU leaders. stated that “while we are still struggling with the Delta variant, we are also threatened by Omicron”.
“What we need to do now is to save time, to reduce the spread of Omicron as much as possible. The means are the triple vaccination, of course the masks, the distances, the reduction of contacts”, the President of the Commission pointed out and assured that there is an adequacy of vaccines and preparations are underway for their possible adaptation.
As he pointed out, he informed the leaders at the Summit that “the contracts [για την προμήθεια των εμβολίων] predict that companies will develop custom vaccines, if requested, within 100 days. ”